Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Community Acquired Pneumonia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Community Acquired Pneumonia - Pipeline Review, H1 2015', provides an overview of the Community Acquired Pneumonia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Community Acquired Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Pneumonia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Community Acquired Pneumonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Community Acquired Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Community Acquired Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Community Acquired Pneumonia Overview 6 Therapeutics Development 7 Pipeline Products for Community Acquired Pneumonia - Overview 7 Pipeline Products for Community Acquired Pneumonia - Comparative Analysis 8 Community Acquired Pneumonia - Therapeutics under Development by Companies 9 Community Acquired Pneumonia - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Community Acquired Pneumonia - Products under Development by Companies 14 Community Acquired Pneumonia - Companies Involved in Therapeutics Development 15 Actavis plc 15 AstraZeneca PLC 16 Biotest AG 17 C10 Pharma AS 18 Kyorin Pharmaceutical Co., Ltd. 19 Paratek Pharmaceuticals, Inc. 20 TaiGen Biotechnology Co., Ltd. 21 Takeda Pharmaceutical Company Limited 22 Community Acquired Pneumonia - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 BT-086 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 C-10 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ceftaroline fosamil - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 dalbavancin - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 KRPAM-1977X - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 nemonoxacin - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 omadacycline - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecules for SSTI and CAP Infections - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 ticagrelor - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Community Acquired Pneumonia - Recent Pipeline Updates 50 Community Acquired Pneumonia - Dormant Projects 65 Community Acquired Pneumonia - Discontinued Products 66 Community Acquired Pneumonia - Product Development Milestones 67 Featured News & Press Releases 67 Oct 03, 2014: FDA Grants Durata Therapeutics a Special Protocol Agreement for Its Phase 3 Study of DALVANCE in Hospitalized Community-Acquired Pneumonia 67 Sep 11, 2013: New Antibiotic Shows Promise for Treating MRSA Pneumonia 67 May 16, 2013: TaiGen Biotechnology Submits New Drug Application For Nemonoxacin In Taiwan And China 68 Aug 28, 2012: European Commission Approves Zinforo To Treat Skin Infections Or Community Acquired Pneumonia 69 Jun 22, 2012: CHPM Adopts Positive Opinion For Zinforo For Treatment Of Complicated Skin And Soft Tissue Infections 69 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 72 Disclaimer 72
List of Tables Number of Products under Development for Community Acquired Pneumonia, H1 2015 7 Number of Products under Development for Community Acquired Pneumonia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Community Acquired Pneumonia - Pipeline by Actavis plc, H1 2015 15 Community Acquired Pneumonia - Pipeline by AstraZeneca PLC, H1 2015 16 Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2015 17 Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H1 2015 18 Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 19 Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 20 Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 21 Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 22 Assessment by Monotherapy Products, H1 2015 23 Number of Products by Stage and Target, H1 2015 25 Number of Products by Stage and Mechanism of Action, H1 2015 27 Number of Products by Stage and Route of Administration, H1 2015 29 Number of Products by Stage and Molecule Type, H1 2015 31 Community Acquired Pneumonia Therapeutics - Recent Pipeline Updates, H1 2015 50 Community Acquired Pneumonia - Dormant Projects, H1 2015 65 Community Acquired Pneumonia - Discontinued Products, H1 2015 66
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
